» Articles » PMID: 19540062

Volumetric Modulated Arc Therapy: Planning and Evaluation for Prostate Cancer Cases

Overview
Specialties Oncology
Radiology
Date 2009 Jun 23
PMID 19540062
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To develop an optimization method using volumetric modulated arc therapy (VMAT) and evaluate VMAT plans relative to the standard intensity-modulated radiotherapy (IMRT) approach in prostate cancer.

Methods And Materials: A single gantry rotation was modeled using 177 equispaced beams. Multileaf collimator apertures and dose rates were optimized with respect to gantry angle subject to dose-volume-based objectives. Our VMAT implementation used conjugate gradient descent to optimize dose rate, and stochastic sampling to find optimal multileaf collimator leaf positions. A treatment planning study of 11 prostate cancer patients with a prescription dose of 86.4 Gy was performed to compare VMAT with a standard five-field IMRT approach. Plan evaluation statistics included the percentage of planning target volume (PTV) receiving 95% of prescribed dose (V95), dose to 95% of PTV (D95), mean PTV dose, tumor control probability, and dosimetric endpoints of normal organs, whereas monitor unit (MU) and delivery time were used to assess delivery efficiency.

Results: Patient-averaged PTV V95, D95, mean dose, and tumor control probability in VMAT plans were 96%, 82.6 Gy, 88.5 Gy, and 0.920, respectively, vs. 97%, 84.0 Gy, 88.9 Gy, and 0.929 in IMRT plans. All critical structure dose requirements were met. The VMAT plans presented better rectal wall sparing, with a reduction of 1.5% in normal tissue complication probability. An advantage of VMAT plans was that the average number of MUs (290 MU) was less than for IMRT plans (642 MU).

Conclusion: The VMAT technique can reduce beam on time by up to 55% while maintaining dosimetric quality comparable to that of the standard IMRT approach.

Citing Articles

Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer.

Johannesson V, Wieslander E, Nilsson P, Brun E, Bitzen U, Ahlgren G Phys Imaging Radiat Oncol. 2021; 18:5-10.

PMID: 34258401 PMC: 8254191. DOI: 10.1016/j.phro.2021.03.001.


Impact of prostate focused alignment on planned pelvic lymph node dose.

Kilian-Meneghin J, Ma T, Kumaraswamy L J Appl Clin Med Phys. 2021; 22(7):27-35.

PMID: 34231945 PMC: 8292696. DOI: 10.1002/acm2.13092.


Evaluation of a new foetal shielding device for pregnant brain tumour patients.

Kang S, Kim K, Kang S, Shin D, Lee S, Chung J Radiat Oncol. 2021; 16(1):109.

PMID: 34120633 PMC: 8201726. DOI: 10.1186/s13014-021-01836-z.


A Novel Machine Learning Model for Dose Prediction in Prostate Volumetric Modulated Arc Therapy Using Output Initialization and Optimization Priorities.

Jensen P, Zhang J, Koontz B, Wu Q Front Artif Intell. 2021; 4:624038.

PMID: 33969289 PMC: 8103207. DOI: 10.3389/frai.2021.624038.


Prostate Stereotactic Body Radiation Therapy With Halcyon 2.0: Treatment Plans Comparison Based on RTOG 0938 Protocol.

Altundal Y, Cifter F, Mu G, Lee J, Wu E, Yeung V Cureus. 2021; 12(11):e11660.

PMID: 33391899 PMC: 7772112. DOI: 10.7759/cureus.11660.